Leptin reduces the accumulation of Aβ and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices

Journal of Alzheimer's Disease

Volumn 19, Issue 3, 2010, Pages 1007-1019

  Marwarha, Gurdeep ^a   Dasari, Bhanu ^a   Prasanthi, Jaya R P ^a   Schommer, Jared ^a   Ghribi, Othman ^a  

^a UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

27 hydroxycholesterol; BACE 1; Cholesterol; GSK 3 ; Hippocampus; Leptin; Organotypic slices; Tau

Indexed keywords

26 HYDROXYCHOLESTEROL; AMYLOID BETA PROTEIN; BETA SECRETASE; BETA SECRETASE 1; GLYCOGEN SYNTHASE KINASE 3BETA; LEPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; OXYSTEROL; OXYSTEROL 27; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DENSITOMETRY; ENZYME INHIBITION; FEEDING BEHAVIOR; HIPPOCAMPUS; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 77149145513     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1298     Document Type: Article

References (54)

1. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
2. Wolozin B (2004) Cholesterol and the biology of Alzheimer's disease. Neuron 41, 7-10.
3. Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant- Thomas T, Wang R, Tint GS, Sambamurti K, Duff K (2000) Hypercholesterolemia upon differentiation associated increases in tau and cyclin-dependent kinase accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
4. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloidpeptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A 98, 5856-5861.
5. Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, Fumagalli R, Govoni S, Trabucchi M, Soma M (1997) Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 322, 893-898.
6. Galbete JL, Martin TR, Peressini E, Modena P, Bianchi R, Forloni G (2000) Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem J 348, 307-313.
7. Lange Y, Ye J, Rigney M, Steck TL (1999) Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J Lipid Res 40, 2264-2270.
8. Vaya J, Schipper HM (2007) Oxysterols, cholesterol homeostasis, and Alzheimer disease. J Neurochem 102, 1727-1737.
9. Heverin M, Meaney S, Lutjohann D, Diczfalusy U, Wahren J, Bjorkhem I (2005) Crossing the barrier: Net flux of 27- hydroxycholesterol into the human brain. J Lipid Res 46, 1047-1052.
10. Haass C, Selkoe DJ (1993) Cellular processing of betaamyloid precursor protein and the genesis of amyloid betapeptide. Cell 75, 1039-1042.
11. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Leoloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
12. Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43, 605-608.
13. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miles MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa E (2006) RAGE, LRP-1, and amyloidbeta protein in Alzheimer's disease. Acta Neuropathol 112, 405-415.
14. Kurochkin IV, Goto S (1994) Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345, 33-37.
15. Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32, 177-180.
16. Leissring MA, FarrisW, Chang AY,Walsh DM,Wu X, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis of betaamyloid in APP transgenic mice prevents plaque formation, secondary pathology and premature death. Neuron 40, 1087-1093.
17. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid-beta protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167.
18. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ (2004) Partial loss of function mutations in insulin-degrading enzyme that induce diabetes also impair degradation amyloid-beta protein. Am J Pathol 164, 1425-1434 .
19. Perez A, Morelli L, Cresto JC, Castano EM (2000) Degradation of soluble amyloid-beta peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 25, 247-255.
20. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM (2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 28, 824-830.
21. Sharma S, Prasanthi JRP, Schommer E, Feist G, Ghribi O (2008) Hypercholesterolemia-induced Aβ accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol Dis 32, 426-432.
22. Prasanthi JRP, Schommer E, Thomasson S, Thompson A, Ghribi O (2008) Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech Ageing Dev 129, 649-655.
23. Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK,Wolozin B, Perry G, Zhu X, Greco SJ, Sarkar S (2009) Leptin: A novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis 16, 731-740.
24. Li HY, Wang LL, Yeh RS (1999) Leptin immunoreactivity in the central nervous system in normal and diabetic rats. Neuroreport 10, 437-442.
25. Ur E,Wilkinson DA, Morash BA,Wilkinson M(2002) Leptin immunoreactivity is localized to neurons in rat brain. Neuroendocrinology 75, 264-272.
26. Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, Tezapsidis N (2004) Obesity-related leptin regulates Alzheimer's Aβ. FASEB J 18, 1870-1878.
27. Greco SJ, Sarkar S, Johnston JM, Zhu X, Su B, Casadesus G, Ashford JW, Smith MA, Tezapsidis N (2008) Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun 376, 536-541.
28. Sweeney G (2002) Leptin signaling. Cell Signaling 14, 655-663.
29. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.
30. Shaw P, Cohen M, Alessi DR (1997) Further evidence that inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett 416, 307-311.
31. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439.
32. Ghribi O, Larsen B, Schrag M, Herman MM (2006) High cholesterol content in neurons increases BACE, β-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol 200, 460-467.
33. Huang XF, Koutcherov I, Lin S, Wang HQ, Storlien L (1996) Localization of leptin receptor mRNA expression in mouse brain. NeuroReport 7, 2635-2638.
34. Ghribi O (2008) Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimers Dis 15, 673-684.
35. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126, 88-94.
36. Sparks DL, Kuo YM, Roher A, Martin T, Lukas RJ (2000) Alterations in Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci 903, 335-344.
37. Sparks DL, Schreurs BG (2003) Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A 100, 11065-11069.
38. Elder GA, Cho JY, English DF, Franciosi S, Schmeidler J, Gama Sosa MA, De Gasperi R, Fisher EA, Matthews PM, Haroutunian V, Buxbaum J (2007) Elevated plasma cholesterol does not affect brain Aβ in mice lacking the low-density lipoprotein receptor. J Neurochem 102, 1220-1231.
39. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Papolla (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
40. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC (2002) Diet-induced hypercholesterolemia enhances brain Abeta accumulation in transgenic mice. Neuroreport 13, 455-459.
41. Graur D, Duret L, Gouy M (1996) Phylogenetic position of the order Lagomorpha (rabbits, hares and allies). Nature 379, 333-335.
42. Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP (1991) Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res 10, 299-305.
43. Brown AJ, Jessup W (1999) Oxysterols and atherosclerosis. Atherosclerosis 142, 1-28.
44. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Brettilon L, Diczfalusy U, Winblad B, Bjorkhem I (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res 45, 186-193.
45. Prasanthi JR, Huls A, Thomasson S, Thompson A, Schommer E, Ghribi O (2009) Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on betaamyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol Neurodegener 4, 1.
46. Kim WS, Chan SL, Hill AF, Guillemin GJ, Garner B (2009) Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J Alzheimers Dis 16, 121-131.
47. Brown J III, Theisler C, Silberman S, Magnuson D, Gottardi- Littell N, Lee JM,Yager D, Crowley J, SambamurtiK,Rahman MM, Reiss AB, Eckman CB, Wolozin B (2004) Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 379, 34674-34681. (Pubitemid 39318097)
48. Sparks DL (2008) The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer's disease: The old, the new and the pilot. J Alzheimers Dis 15, 641-656.
49. Woodruff-Pak DS, Agelan A, Del Valle L (2007) A rabbit model of Alzheimer's disease: Valid at neuropathological, cognitive, and therapeutic levels. J Alzheimers Dis 11, 371-383.
50. Garza JC, Guo M, Zhang W, Lu XY (2008) Leptin increases adult hippocampal neurogenesis in vivo and in vitro. J Biol Chem 283, 18238-18247.
51. Greco SJ, Sarkar S, Johnston JM, Tezapsidis N (2009) Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun 380, 98-104.
52. Greco SJ, Sarkar S, Casadesus G, Zhu X, Smith MA, Ashford JW, Johnston JM, Tezapsidis N (2009) Leptin inhibits glycogen synthase kinase-3β to prevent tau phosphorylation in neuronal cells. Neurosci Lett 455, 191-194.
53. Wang QM, Fiol CJ, DePaoli-Roach AA, Roach PJ (1994) Glycogen synthase kinase- 3β is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem 269, 14566-14574.
54. Kim L, Liu J, Kimmel AR (1999) The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell 99, 399-408.